Organon & Co | OGN - Fremdkapital





Fremdkapital Veränderung Datum
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Celltrion KRW 412.27B 348.97B 2025-12
Cspc Pharmaceutical CNY 180.69M 21.94M 2025-12
Deva Holding AS TRY 559.97M 44.39M 2023-09
Dianthus Therapeutics USD 0 0 2024-12
Divis Laboratories Ltd INR 50M 30M 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
Glaxosmithkline GBP 19.82B 203.13M 2025-12
Kangmei Pharma CNY 68.57M 9.87M 2026-03
Knight Therapeutics CAD 57.78M 26.92M 2025-12
Laboratorios Farma EUR 80.5M 28.26M 2024-12
Malin Corporation EUR 0 0 2024-12
Medical Developments International AUD 1.5M 167K 2025-12
Merck USD 46.67B 77M 2026-03
Novartis USD 29.59B 5.35B 2025-12
Organigram Holdings CAD 62.52M 13.88M 2025-12
Organon & Co USD 8.55B 75M 2026-03
Ovoca Bio EUR 0 0 2021-06
Pharma Mar EUR 33.16M 3.52M 2026-03
Qiagen NV USD 1.65B 15.23M 2025-12
Sartorius EUR 3.34B 152.8M 2026-03
Sino Biopharmaceutical CNY 3.08B 1B 2025-06
Tilray USD 268.59M 3.82M 2025-09
Zealand Pharma A/S 383.14M 727K 2025-12